Exploring the prevalence and burden of sleep disturbance in primary brain tumor patients.

Autor: King AL; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Shuboni-Mulligan DD; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Vera E; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Crandon S; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Acquaye AA; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Boris L; Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA., Burton E; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Choi A; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Christ A; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Grajkowska E; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Jammula V; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Leeper HE; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Lollo N; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Penas-Prado M; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Reyes J; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Theeler B; Walter Reed National Military Medical Center, Bethesda, Maryland, USA., Wall K; Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA., Wu J; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Gilbert MR; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Armstrong TS; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jazyk: angličtina
Zdroj: Neuro-oncology practice [Neurooncol Pract] 2022 Jun 22; Vol. 9 (6), pp. 526-535. Date of Electronic Publication: 2022 Jun 22 (Print Publication: 2022).
DOI: 10.1093/nop/npac049
Abstrakt: Background: Sleep disturbance (SD) is common in patients with cancer and has been associated with worse clinical outcomes. This cross-sectional study explored the prevalence of SD in a primary brain tumor (PBT) population, identified associated demographic and clinical characteristics, and investigated co-occurrence of SD with other symptoms and mood disturbance.
Methods: Demographic, clinical characteristics, MD Anderson Symptom Inventory-Brain Tumor, and Patient Reported Outcome Measurement Information System Depression and Anxiety Short-Forms were collected from PBT patients at study entry. Descriptive statistics, Chi-square tests, and independent t -tests were used to report results.
Results: The sample included 424 patients (58% male, 81% Caucasian) with a mean age of 49 years (range 18-81) and 58% with high-grade gliomas. Moderate-severe SD was reported in 19% of patients and was associated with younger age, poor Karnofsky Performance Status, tumor progression on MRI, and active corticosteroid use. Those with moderate-severe SD had higher overall symptom burden and reported more moderate-severe symptoms. These individuals also reported higher severity in affective and mood disturbance domains, with 3 to 4 times higher prevalence of depressive and anxiety symptoms, respectively. The most frequently co-occurring symptoms with SD were, drowsiness, and distress, though other symptoms typically associated with tumor progression also frequently co-occurred.
Conclusions: PBT patients with moderate-severe SD are more symptomatic, have worse mood disturbance, and have several co-occurring symptoms. Targeting interventions for sleep could potentially alleviate other co-occurring symptoms, which may improve life quality for PBT patients. Future longitudinal work examining objective and detailed subjective sleep reports, as well as underlying genetic risk factors, will be important.
(Published by Oxford University Press 2022.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje